Abstract
Background: Previous studies suggested that metformin treatment could affect the survival outcomes of endometrial cancer (EC). This meta-analysis aims to investigate the prognostic value of metformin use in patients with EC. Methods: Pubmed and Embase databases were searched from inception to November 2019. We analyzed the association between metformin intake and survival of EC. Summary hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using the random-effects model. The primary outcome was overall survival (OS) and the secondary outcome was progression-free survival (PFS). Results: A total of eight cohort studies enrolling 6911 participants were eligible for this meta-analysis. For patients with diabetes mellitus (DM), the pooled results showed metformin could significantly improve the OS (HR=0.57, 95% CI 0.42 to 0.78) and PFS (HR=0.61, 95% CI 0.46 to 0.80,). However, no significant difference in OS (HR= 0.79, 95% CI 0.58 to 1.08) and PFS (HR=1.05, 95% CI 0.93 to1.19) was found between the patients with diabetes who used metformin and the subjects without diabetes. Conclusions: This study showed, based on only a limited number of studies, that metformin use was significantly associated a favorable survival outcome with of EC in diabetes patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
